For example, MAGEA6-AMPK signaling is activated by knock-out IGF2BP1 with CRISPR/Cas9, resulting in the apoptosis of glioma cells (A172) and inhibiting the survival of human glioma cells, so as to achieve a therapeutic effect [108]. This evidence concerns the gene IGF2BP1 and central nervous system cancer.